Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Annayyaon Jun 15, 2021 11:19am
135 Views
Post# 33388374

RE:RE:Game Plan

RE:RE:Game PlanI understand sell the news as I have done it many times but theres times when the price should hold. I don't see Biogen's price falling below $400 after going up over 40% since Friday June 4th before the news. You might be right that the PMN shareholders didn't see significant news from PMN in a week following the aducanumab approval so they decided to sell impatiently. This is the reason why I said we need partnership with big pharma or some other large investor group news right away. We have come far from where PMN310 was 3 years ago as you know, and you remember they were talking about major partnership for years now to start phase 1 but had excuses for delays. The approval of aducanumab clears all those excuses now.
retiredcop wrote: Who.let the share price.fall? Have you not figured out that many of the shareholders around us.on this message board have figured how this game.works....price goes up on news....wait to see if there is.more.coming ...if not sell at the higher price then work.on driving the stock.back.down and relaying the game....maybe if a someone out there maybe points out how.much money they made last week and now how much they are rebuying..


<< Previous
Bullboard Posts
Next >>